Skip to Main Content

INFORMATION FOR

Timothy Robinson, MD, PhD

Assistant Professor of Therapeutic Radiology

Contact Information

Timothy Robinson, MD, PhD

Research Summary

Dr. Robinson has a clinical research program focused on the emerging roles of therapeutic radiation in hematologic and secondary CNS malignancies in combination with CAR T-cell and other immune-based therapies. His translational research program is focused on the role of alternative splicing in cancer, particularly with respect to its role in mediating cellular and immune therapy resistance.

Research Interests

Immunotherapy

Selected Publications

  • Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell LymphomasFigura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.
  • Oral Mucosal Sparing in High-Dose Total Body Irradiation (TBI) prior to Stem Cell Transplantation (SCT) for Acute LeukemiaLiveringhouse C, Sandoval M, Dohm A, Weygand J, Garcia G, Peters J, Nieder M, Faramand R, Jain M, Locke F, Bejanyan N, Kim S, Robinson T, Latifi K. Oral Mucosal Sparing in High-Dose Total Body Irradiation (TBI) prior to Stem Cell Transplantation (SCT) for Acute Leukemia International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e353. DOI: 10.1016/j.ijrobp.2022.07.1462.
  • PD01-09 PROTEOGENOMIC AND CLINICAL IMPLICATIONS OF RECURRENT SPLICE VARIANTS IN CLEAR CELL RENAL CELL CARCINOMAChang A, Stewart P, Chakiryan N, Soupir A, Tian Y, Du D, Teer J, Kim Y, Spiess P, Chahoud J, Zhang Y, Koomen J, Berglund A, Robinson T, Wang L, Manley B. PD01-09 PROTEOGENOMIC AND CLINICAL IMPLICATIONS OF RECURRENT SPLICE VARIANTS IN CLEAR CELL RENAL CELL CARCINOMA Investigative Urology 2022, 207: e33. DOI: 10.1097/ju.0000000000002516.09.
  • Proteogenomic and clinical implications of unique recurrent splice variants in clear cell renal cell carcinoma.Chang A, Stewart P, Chakiryan N, Soupir A, Tian Y, Du D, Teer J, Kim Y, Spiess P, Chahoud J, Zhang Y, Koomen J, Berglund A, Wang L, Robinson T, Manley B. Proteogenomic and clinical implications of unique recurrent splice variants in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 380-380. DOI: 10.1200/jco.2022.40.6_suppl.380.
  • Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain MetastasesDohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.
  • NCMP-08. CHALLENGING DIAGNOSIS AND MANAGEMENT OF PCNSL IN AN IMMUNOSUPPRESSED PATIENT ON MYCOPHENOLATE MOFETIL FOR MYASTHENIA GRAVISBricoune O, Mokhtari S, Etame A, Robinson T, Pina Y, Macaulay R. NCMP-08. CHALLENGING DIAGNOSIS AND MANAGEMENT OF PCNSL IN AN IMMUNOSUPPRESSED PATIENT ON MYCOPHENOLATE MOFETIL FOR MYASTHENIA GRAVIS Neuro-Oncology 2021, 23: vi148-vi149. DOI: 10.1093/neuonc/noab196.581.
  • Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With OutcomeRishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass D, Ahmed K. Immune Cell Infiltrates of the Tumor Microenvironment and Radiosensitivity of Recurrent Glioblastomas and Their Association With Outcome International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s123. DOI: 10.1016/j.ijrobp.2021.07.281.
  • In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell LymphomasSim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.
  • Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy AloneDohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e567. DOI: 10.1016/j.ijrobp.2021.07.1531.
  • Dosimetric Comparison of Volumetric Modulated Arc Therapy with Tomotherapy Based Total Body Irradiation for Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation for Acute Lymphocytic LeukemiaLiveringhouse C, Robinson T, Garcia G, Peters J, Kim S, Latifi K. Dosimetric Comparison of Volumetric Modulated Arc Therapy with Tomotherapy Based Total Body Irradiation for Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation for Acute Lymphocytic Leukemia International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e303. DOI: 10.1016/j.ijrobp.2021.07.950.
  • Utilizing Radiation Dose Maps to Predict Local Failure Following Stereotactic Radiation of Brain MetastasesKutuk T, Pandey S, Mills M, Abdalah M, Stringfield O, Latifi K, Robinson T, Ahmed K, Raghunand N. Utilizing Radiation Dose Maps to Predict Local Failure Following Stereotactic Radiation of Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e570-e571. DOI: 10.1016/j.ijrobp.2021.07.1540.
  • MP39-14 IDENTIFICATION OF RECURRENT SOMATIC SPLICE SITE VARIANTS ACROSS MULTIPLE CLEAR CELL RENAL CELL CARCINOMA COHORTSChakiryan N, Robinson T, Du D, Hajiran A, Zemp L, Kim Y, Chahoud J, Spiess P, Wang L, Mule J, Manley B. MP39-14 IDENTIFICATION OF RECURRENT SOMATIC SPLICE SITE VARIANTS ACROSS MULTIPLE CLEAR CELL RENAL CELL CARCINOMA COHORTS Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002054.14.
  • PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell LymphomaFigura N, Sim A, Dahiya S, Lutfi F, Rapoport A, Mohindra P, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma Radiotherapy And Oncology 2021, 161: s894-s895. DOI: 10.1016/s0167-8140(21)07526-5.
  • PH-0224 Association between the genomic immune response and locoregional control in ER- breast cancerLiveringhouse C, Wilson C, Mills M, Thapa R, Fridley B, Robinson T, Diaz R. PH-0224 Association between the genomic immune response and locoregional control in ER- breast cancer Radiotherapy And Oncology 2021, 161: s156. DOI: 10.1016/s0167-8140(21)07276-5.
  • Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.Ahmed K, Kim Y, Arrington J, Kim S, DeJesus M, Soyano A, Armaghani A, Costa R, Khong H, Rosa M, Caudell J, Diaz R, Robinson T, Etame A, Tran N, Sahebjam S, Soliman H, Forsyth P, Yu H, Han H. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study. Journal Of Clinical Oncology 2021, 39: e14010-e14010. DOI: 10.1200/jco.2021.39.15_suppl.e14010.
  • Lymphoplasmacytic Lymphoma Manifesting as a Cervical Spine Mass with Parkinson-Like Symptoms Treated with IbrutinibTan E, Tran N, Peguero E, Robinson T, Gaballa S. Lymphoplasmacytic Lymphoma Manifesting as a Cervical Spine Mass with Parkinson-Like Symptoms Treated with Ibrutinib Current Problems In Cancer Case Reports 2021, 3: 100046. DOI: 10.1016/j.cpccr.2020.100046.
  • Abstract PS14-19: Characteristics of breast cancer brain metastases presentation by subtype and validation of the modified breast graded prognostic assessmentKawahara Y, Fahey M, Potluri T, Mills M, Figura N, Washington I, Diaz R, Robinson T, Yu H, Etame A, Liu J, Vogelbaum M, Czerniecki B, Forsyth P, Soliman H, Han H, Ahmed K. Abstract PS14-19: Characteristics of breast cancer brain metastases presentation by subtype and validation of the modified breast graded prognostic assessment Cancer Research 2021, 81: ps14-19-ps14-19. DOI: 10.1158/1538-7445.sabcs20-ps14-19.
  • Abstract SS1-11: Comprehensive analysis of health services, sociodemographic, clinical, and genomic factors driving locally advanced breast cancer mortality via a first-in-kind linkage of SEER-Medicare data with physical tumor samplesRobinson T, Wilson L, Marcom P, Troester M, Lynch C, Hernandez B, Castellar E, Brauer H, Enewold L, Dinan M. Abstract SS1-11: Comprehensive analysis of health services, sociodemographic, clinical, and genomic factors driving locally advanced breast cancer mortality via a first-in-kind linkage of SEER-Medicare data with physical tumor samples Cancer Research 2021, 81: ss1-11-ss1-11. DOI: 10.1158/1538-7445.sabcs20-ss1-11.
  • RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATIONThawani C, Mills M, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION Neuro-Oncology 2020, 22: ii181-ii182. PMCID: PMC7651564, DOI: 10.1093/neuonc/noaa215.757.
  • TAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVALRishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass G, Ahmed K. TAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVAL Neuro-Oncology 2020, 22: ii225-ii225. PMCID: PMC7651565, DOI: 10.1093/neuonc/noaa215.941.
  • Brain Metastases Outcomes In Patients With Melanoma, Non-Small Cell Lung Cancer, And Breast Cancer And Implications For Screening Brain MRIsPotluri T, Fahey M, Kawahara Y, Mills M, Figura N, Washington I, Diaz R, Robinson T, Yu H, Etame A, Czerniecki B, Arrington J, Forsyth P, Soliman H, Han H, Ahmed K. Brain Metastases Outcomes In Patients With Melanoma, Non-Small Cell Lung Cancer, And Breast Cancer And Implications For Screening Brain MRIs International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e701-e702. DOI: 10.1016/j.ijrobp.2020.07.057.
  • Clinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and CapecitabineMills M, Naz A, Thawani C, Walker C, Figura N, Forsyth P, Etame A, Liu J, Vogelbaum M, Yu M, Robinson T, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e685-e686. DOI: 10.1016/j.ijrobp.2020.07.2040.
  • Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab EmtansineMills M, Walker C, Thawani C, Naz A, Figura N, Yu M, Robinson T, Etame A, Liu J, Vogelbaum M, Forsyth P, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e679-e680. DOI: 10.1016/j.ijrobp.2020.07.2026.
  • Revisiting the Concept of “Local” Recurrence in Primary Central Nervous System Lymphomas (PCNSL) after Complete Response to MTX-based Therapy: Are “Local” Failures Truly Just Periventricular?Kutuk T, Grass D, Oliver D, Mokhtari S, Robinson T. Revisiting the Concept of “Local” Recurrence in Primary Central Nervous System Lymphomas (PCNSL) after Complete Response to MTX-based Therapy: Are “Local” Failures Truly Just Periventricular? International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s156. DOI: 10.1016/j.ijrobp.2020.07.914.
  • OC-0559: Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) TherapyFigura N, Jain M, Sim A, Dean E, Balagurunathan Y, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Kim S, Locke F, Robinson T. OC-0559: Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy Radiotherapy And Oncology 2020, 152: s311-s312. DOI: 10.1016/s0167-8140(21)00581-8.
  • Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic RadiationMills M, Thawani C, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e18-e19. DOI: 10.1016/j.ijrobp.2020.02.508.
  • Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) TherapyFigura N, Jain M, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Kim S, Locke F, Robinson T. Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e51. DOI: 10.1016/j.ijrobp.2020.02.589.
  • Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with Lymphopenia (FLIPI-L) to Predict Overall Survival and Histologic TransformationHooper M, Yang G, Mills M, Figura N, Doyle C, Oliver D, Robinson T, Chavez J, Kim S. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with Lymphopenia (FLIPI-L) to Predict Overall Survival and Histologic Transformation International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e15. DOI: 10.1016/j.ijrobp.2020.02.499.
  • PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMAHajiran* A, Kim Y, Zaman S, Madanyake T, Robinson T, Falasiri S, Spiess P, Kohli M, Boyle T, Mulé J, Teer J, Manley B. PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000918.06.
  • Abstract OT3-10-01: Phase Ib study of stereotactic radiation and nivolumab in the management of metastatic breast cancer with brain metastasesAhmed K, Kim Y, Armaghani A, Arrington J, Caudell J, Costa R, Czerniecki B, Etame A, Forsyth P, Khong H, Kim S, Loftus L, Robinson T, Rosa M, Sahebjam S, Soliman H, Soyano A, Tran N, Yu H, Han H. Abstract OT3-10-01: Phase Ib study of stereotactic radiation and nivolumab in the management of metastatic breast cancer with brain metastases Cancer Research 2020, 80: ot3-10-01-ot3-10-01. DOI: 10.1158/1538-7445.sabcs19-ot3-10-01.
  • ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMASSahebjam S, Forsyth P, Tran N, Etame A, Arrington J, Jaglal M, Mokhtari S, MacAulay R, Wicklund M, Evernden B, Gatewood T, Robinson T, Raval R, Yu M. ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847102, DOI: 10.1093/neuonc/noz175.017.
  • CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMESMohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.
  • Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiotherapy (FSRT) for Sarcoma Brain MetastasesSim A, Ahmed K, Keller A, Figura N, Oliver D, Sarangkasiri S, Robinson T, Johnstone P, Yu M, Naghavi A. Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiotherapy (FSRT) for Sarcoma Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e120. DOI: 10.1016/j.ijrobp.2019.06.2235.
  • Differences in Gene Expression between Black and White Patients with Triple Negative Breast Cancer Is Not Implicated in Locoregional Recurrence RiskWashington I, Liveringhouse C, Mills M, Figura N, Ahmed K, Robinson T, Blumencranz P, Allen K, Laronga C, Wilson C, Fridley B, Diaz R. Differences in Gene Expression between Black and White Patients with Triple Negative Breast Cancer Is Not Implicated in Locoregional Recurrence Risk International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s166. DOI: 10.1016/j.ijrobp.2019.06.190.
  • Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and NivolumabMohammadi H, Tolpin A, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Robinson T, Yu M. Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e82. DOI: 10.1016/j.ijrobp.2019.06.2349.
  • CDK 4/6 Inhibitors and Stereotactic Radiation in the Management of Hormone Receptor-Positive Breast Cancer Brain MetastasesPotluri T, Figura N, Oliver D, Robinson T, Etame A, Tran N, Liu J, Soliman H, Forsyth P, Sahebjam S, Yu M, Han H, Ahmed K. CDK 4/6 Inhibitors and Stereotactic Radiation in the Management of Hormone Receptor-Positive Breast Cancer Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e86. DOI: 10.1016/j.ijrobp.2019.06.2358.
  • Patterns of Failure Following Chimeric Antigen Receptor T-cell (CAR-T) TherapyFigura N, Jain M, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Liu H, Kim S, Locke F, Robinson T. Patterns of Failure Following Chimeric Antigen Receptor T-cell (CAR-T) Therapy International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s66-s67. DOI: 10.1016/j.ijrobp.2019.06.515.
  • OA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation TherapyFigura N, Mohammadi H, Rizk V, Evernden B, Mokhtari S, Yu H, Robinson T, Etame A, Tran N, Diaz R, Soliman H, Han H, Sahebjam S, Forsyth P, Ahmed K. OA15 Clinical Outcomes of Breast Leptomeningeal Disease Treated with Intrathecal Trastuzumab, Intrathecal Chemotherapy, or Whole Brain Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e7. DOI: 10.1016/s0360-3016(19)30416-x.
  • PV-0048 The Radiosensitivity Index (RSI) predicts for outcomes in triple negative breast cancerLiveringhouse C, Figura N, Ahmed K, Grass G, Blumencranz P, Allen K, Laronga C, Lee M, Harrison L, Robinson T, Torres-Roca J, Diaz R. PV-0048 The Radiosensitivity Index (RSI) predicts for outcomes in triple negative breast cancer Radiotherapy And Oncology 2019, 133: s17-s18. DOI: 10.1016/s0167-8140(19)30468-2.
  • Abstract P4-08-15: Locoregional recurrence in invasive breast cancer and association with tumor infiltrating leukocyte (TIL) presenceLiveringhouse C, Grass G, Figura N, Mills M, Purcell J, Rosensweig S, Blumencranz P, Allen K, Ahmed K, Harrison L, Torres-Roca J, Robinson T, Diaz R. Abstract P4-08-15: Locoregional recurrence in invasive breast cancer and association with tumor infiltrating leukocyte (TIL) presence Cancer Research 2019, 79: p4-08-15-p4-08-15. DOI: 10.1158/1538-7445.sabcs18-p4-08-15.
  • Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene CiloleucelJain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel Blood 2018, 132: 4220-4220. DOI: 10.1182/blood-2018-99-117133.
  • ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)Sahebjam S, Forsyth P, Tran N, Mokhtari S, Arrington J, Jaglal M, Etame A, Liu J, Wicklund M, Gatewood T, Macaulay R, Robinson T, Yu M. ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891) Neuro-Oncology 2018, 20: vi2-vi2. PMCID: PMC6216125, DOI: 10.1093/neuonc/noy148.005.
  • Locoregional Recurrence Is Associated With Genomic Down-Regulation of the Immune Response in Women with Locally Invasive Breast CancerLiveringhouse C, Purcell J, Mills M, Diaz R, Robinson T. Locoregional Recurrence Is Associated With Genomic Down-Regulation of the Immune Response in Women with Locally Invasive Breast Cancer International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s67-s68. DOI: 10.1016/j.ijrobp.2018.06.185.
  • Biologic Subtypes of Primary Breast Tumors Exhibit Differences in the Radiosensitivity IndexLiveringhouse C, Ahmed K, Purcell J, Mills M, Grass G, Robinson T, Torres-Roca J, Diaz R. Biologic Subtypes of Primary Breast Tumors Exhibit Differences in the Radiosensitivity Index International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e601-e602. DOI: 10.1016/j.ijrobp.2018.07.1652.
  • Response to Local Treatment Modalities in Patients with Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell LymphomaYuan Z, Grass G, Robinson T, Kim S. Response to Local Treatment Modalities in Patients with Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e379-e380. DOI: 10.1016/j.ijrobp.2018.07.1130.
  • Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain MetastasesSavla B, Ahmed K, Yu M, Perez B, Dinan M, Mason N, Robinson T. Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e105. DOI: 10.1016/j.ijrobp.2017.06.842.
  • Pretreatment T2-Weighted Fluid Attenuated Inversion Recovery (T2-FLAIRpre) MRI May Improve Gross Tumor Volume Delineation for Recurrent Glioblastoma Treated with Salvage Hypofractionated Stereotactic Radiation TherapyChou K, Grass G, Zhang G, Latifi K, Arrington J, Sahebjam S, Raghunand N, Enderling H, Stringfield O, Sarangkasiri S, Forsyth P, Johnstone P, Robinson T, Yu H. Pretreatment T2-Weighted Fluid Attenuated Inversion Recovery (T2-FLAIRpre) MRI May Improve Gross Tumor Volume Delineation for Recurrent Glioblastoma Treated with Salvage Hypofractionated Stereotactic Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e650. DOI: 10.1016/j.ijrobp.2017.06.2170.
  • Correlation of Molecular Features With Clinical Outcomes in Glioblastoma Treated with ChemoradiationLiveringhouse C, Grass G, Ahmed K, Naghavi A, Macaulay R, Etame A, Tran N, Forsyth P, Sahebjam S, Johnstone P, Robinson T, Yu M. Correlation of Molecular Features With Clinical Outcomes in Glioblastoma Treated with Chemoradiation International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e605-e606. DOI: 10.1016/j.ijrobp.2017.06.2058.
  • Management of Double/Triple Hit Early Stage Diffuse Large B-Cell Lymphoma With Radiation TherapyMills M, Grass G, Liveringhouse C, Ahmed K, Robinson T, Montejo M, Kim S. Management of Double/Triple Hit Early Stage Diffuse Large B-Cell Lymphoma With Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s53-s54. DOI: 10.1016/j.ijrobp.2017.06.135.
  • A Comparison of Outcomes in Recurrent High Grade Gliomas Treated With Hypofractionated Stereotactic Radiation Therapy With or Without Programmed Cell Death Protein 1 (PD-1) BlockadeGrass G, Sahebjam S, Macaulay R, Forsyth P, Tran N, Etame A, Arrington J, Sarangkasiri S, Johnstone P, Robinson T, Yu H. A Comparison of Outcomes in Recurrent High Grade Gliomas Treated With Hypofractionated Stereotactic Radiation Therapy With or Without Programmed Cell Death Protein 1 (PD-1) Blockade International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s102. DOI: 10.1016/j.ijrobp.2017.06.244.
  • Radiomics-Based Characterization of Recurrence Risk in Primary CNS LymphomaGrass G, Latifi K, Oliver D, Bello C, Forsyth P, Carney G, Gillies R, Stringfield O, Robinson T. Radiomics-Based Characterization of Recurrence Risk in Primary CNS Lymphoma International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e591. DOI: 10.1016/j.ijrobp.2017.06.2024.
  • Abstract 1232: Development of novel therapeutic splice-switching oligonucleotides targeting oncogenic RNA isoforms driving race-related aggressive prostate cancerFreedman J, Robinson T, LaCroix B, Patierno B, George D, Sullenger B, Patierno S. Abstract 1232: Development of novel therapeutic splice-switching oligonucleotides targeting oncogenic RNA isoforms driving race-related aggressive prostate cancer Cancer Research 2017, 77: 1232-1232. DOI: 10.1158/1538-7445.am2017-1232.
  • (P019) LINAC-Based Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Brain Metastases From SarcomaKeller A, Yu M, Naghavi A, Robinson T, Sarangkasiri S, Etame A, Johnstone P, Ahmed K. (P019) LINAC-Based Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Brain Metastases From Sarcoma International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e20-e21. DOI: 10.1016/j.ijrobp.2017.02.116.
  • Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931).Sahebjam S, Forsyth P, Arrington J, Tran N, Jaglal M, Mokhtari S, Long W, Macaulay R, Wicklund M, Drury-Sibiga A, Gatewood T, Robinson T, Raval R, Yu M. Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931). Journal Of Clinical Oncology 2017, 35: tps2084-tps2084. DOI: 10.1200/jco.2017.35.15_suppl.tps2084.
  • Abstract LB-015: XIAP induction by the MAPK-eIF4G1 pathway drives NFκB activation in inflammatory breast cancer growth and therapeutic resistanceEvans M, Geradts J, Edwards C, Price A, Arora A, Aldrich A, Ramirez A, Robinson T, Vermeulen P, van Laere S, Devi G. Abstract LB-015: XIAP induction by the MAPK-eIF4G1 pathway drives NFκB activation in inflammatory breast cancer growth and therapeutic resistance Cancer Research 2016, 76: lb-015-lb-015. DOI: 10.1158/1538-7445.am2016-lb-015.
  • Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descentFreedman J, Robinson T, LaCroix B, Patierno B, George D, Sullenger B, Patierno S. Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent Cancer Epidemiology Biomarkers & Prevention 2016, 25: b18-b18. DOI: 10.1158/1538-7755.disp15-b18.
  • Next Generation Sequencing of Sarcoma Cells With HIF-1α Deletion Reveals Context-Dependent Regulation of HIF-1 Transcriptional Targets Induced by Radiation Versus HypoxiaRobinson T, Zhang M, Kirsch D. Next Generation Sequencing of Sarcoma Cells With HIF-1α Deletion Reveals Context-Dependent Regulation of HIF-1 Transcriptional Targets Induced by Radiation Versus Hypoxia International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186. DOI: 10.1016/j.ijrobp.2015.07.445.
  • Hypoxia Induces mRNA 3’UTR Truncation in Multiple Cell Types In VitroRobinson T, Chi J, Dewhirst M. Hypoxia Induces mRNA 3’UTR Truncation in Multiple Cell Types In Vitro International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s824. DOI: 10.1016/j.ijrobp.2014.05.2373.
  • Detection of Novel Hypoxia-Induced Changes in Alternative mRNA Processing Associated With Clinical Prognosis in Adenocarcinoma of the LungRobinson T, Dewhirst M. Detection of Novel Hypoxia-Induced Changes in Alternative mRNA Processing Associated With Clinical Prognosis in Adenocarcinoma of the Lung International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s664. DOI: 10.1016/j.ijrobp.2013.06.1759.
  • Longitudinal Trends in Costs for Palliative Radiation for Metastatic Prostate CancerRobinson T, Dinan M, Li Y, Lee W, Reed S. Longitudinal Trends in Costs for Palliative Radiation for Metastatic Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s490. DOI: 10.1016/j.ijrobp.2013.06.1294.
  • Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.
  • EBV-regulated global changes in mRNA isoform usageHoma N, Salinas R, Forte E, Robinson T, Garcia-Blanco M, Luftig M. EBV-regulated global changes in mRNA isoform usage Infectious Agents And Cancer 2012, 7: o3. PMCID: PMC3330090, DOI: 10.1186/1750-9378-7-s1-o3.
  • Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries.Dinan M, Robinson T, Zagar T, Scales C, Curtis L, Reed S, Schulman K, Lee W. Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries. Journal Of Clinical Oncology 2011, 29: 6115-6115. DOI: 10.1200/jco.2011.29.15_suppl.6115.